Cobra Biologics & Algeta Sign Monoclonal Antibody Agreement
Cobra Biologics Ltd and Algeta ASA recently announced a new contract manufacturing partnership for Algeta’s fourth Targeted Thorium Conjugate (TTC) program. The program will focus on the development of an undisclosed monoclonal antibody, which is highly selective for a validated cell surface target on hematological cancer cells, linked to Algeta’s alpha-particle emitter thorium-227 (Th-227).
Under the terms of the contract manufacturing agreement, Cobra will be providing cell line development through its maxXpress service, GMP cell banking, analytical and process development, scale-up, toxicology, and GMP production, as well as stability studies.
Algeta will be benefiting from Cobra’s maxXpress service, which combines the UCOE protein expression technology with the experience and expertise of Cobra Biologics’ cell line development team and the Cello robotic clone selection system, to enable rapid clone selection and production of the monoclonal antibody.
“We are delighted that Algeta has chosen Cobra as the manufacturer of a monoclonal antibody,” said Peter Coleman, CEO of Cobra Biologics. “Algeta’s contract forms part of a very successful year in which we are seeing significant expansion in our antibody contract manufacturing as customers see the advantages Cobra’s comprehensive services provide.”
Cobra Biologics is a leading international clinical and commercial contract manufacturer of biologics and pharmaceuticals with three GMP-approved facilities. It offers a broad range of integrated and stand-alone development services, stretching from cell line development through to the commercial supply of medicinal products. For more information, please visit www.cobrabio.com.
Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. The company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA. performing commercial operations. For more information, please visit www.algeta.com.
Total Page Views: 883
